# Lifespan Vision Ventures

> Lifespan Vision Ventures is a VC fund backing Biotechnology and Health Care. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Norwalk, United States
- Total investments: 19
- Last investment: Aug 2026
- Lead investor: 58%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/lifespan-vision-ventures
- Website: https://www.lifespanvisionventures.com

Lifespan Vision Ventures is a VC fund in Norwalk focused on Biotechnology and Health Care. Lifespan Vision Ventures invests in companies that develop therapeutics focusing on longevity and aging reversal.

## Contacts

5 contacts available for Lifespan Vision Ventures. Shizune tracks 1 team members at Lifespan Vision Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifespan-vision-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 58% |
| Health Care | 6 | 32% |
| Medical | 3 | 16% |
| Life Science | 3 | 16% |
| Therapeutics | 3 | 16% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 32% |
| Series A | 3 | 16% |
| Funding Round | 3 | 16% |
| Venture - Series Unknown | 2 | 11% |
| Pre-Seed | 1 | 5% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 42% |
| United Kingdom | 2 | 11% |
| Switzerland | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Altar Munis | Associate | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Remedium Bio | Remedium Bio is a Boston area gene therapy company focused on the development of curative treatments for a number of highly debilitating conditions. Our fundamental approach to product development utilizes proven technologies in novel ways to treat well-characterized disease pathology. To streamline R&D, we modularly apply elements of proventechnology to develop local, targeted treatments focusing on clinically validated molecules and mechanistic pathways. Today, our leading candidates include gene therapy treatments in the fields of Rheumatology / Osteoarthritis, Endocrinology / Diabetes, and Neurology / Stroke. | $10M | Series A | Aug 10, 2026 |  |
| Violet Therapeutics | Violet Therapeutics is a healthcare company that operates in stealth mode. | $4.8M | Seed | May 13, 2026 |  |
| Violet Therapeutics | Violet Therapeutics is a healthcare company that operates in stealth mode. | $4.8M | Seed | May 13, 2026 |  |
| TECregen | TECregen is a biotechnology company that develops thymus-rejuvenating biologics to restore immune function and T-cell responses. | $12.5M | Seed | Jan 08, 2026 |  |
| Sift Biosciences | Sift Biosciences is a biotechnology research company that offers cancer therapies. | $3.8M | Pre-Seed | Dec 19, 2025 |  |
| EpiBone | EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. |  | Convertible Note | Nov 08, 2024 |  |
| Integrated Biosciences | Integrated Biosciences is the first company in history to be able to virtually stress cells. | $17.2M | Seed | Oct 03, 2024 |  |
| LIfT BioSciences | LIfT Biosciences is a biotech company that develops allogeneic cell therapies using Immunomodulatory Alpha Neutrophils (IMANs) derived from hematopoietic or induced pluripotent stem cells. The company leverages its patented N‑LIfT platform to generate neutrophils capable of directly destroying cancer cells and reprogramming the tumormicroenvironment to enhance immune recruitment. Preclinical data have shown potent activity across multiple solid tumor types, with Phase I clinical trials in metastatic cervical and head‑and‑neck cancer planned in partnership with the University of Galway. | $13.4M | Series A | Sep 24, 2024 |  |
| Remedium Bio | Remedium Bio is a Boston area gene therapy company focused on the development of curative treatments for a number of highly debilitating conditions. Our fundamental approach to product development utilizes proven technologies in novel ways to treat well-characterized disease pathology. To streamline R&D, we modularly apply elements of proventechnology to develop local, targeted treatments focusing on clinically validated molecules and mechanistic pathways. Today, our leading candidates include gene therapy treatments in the fields of Rheumatology / Osteoarthritis, Endocrinology / Diabetes, and Neurology / Stroke. |  | Seed | Sep 10, 2024 |  |
| Immunis | Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline. | $25M | Series A | Jul 01, 2024 |  |

10 of 19 investments shown.

## Co-investors
- [QantX](https://shizune.co/investors/profile/qantx) — VC Fund, 5 deals together
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-2) — VC Fund, 3 deals together
- [Emerging Longevity Ventures](https://shizune.co/investors/profile/emerging-longevity-ventures) — VC Fund, 3 deals together
- [R42 Group](https://shizune.co/investors/profile/r42-group) — VC Fund, 3 deals together
- [Trend Investment Group](https://shizune.co/investors/profile/trend-investment-group) — VC Fund, 3 deals together
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-12df) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Lifespan Vision Ventures invest in?

Lifespan Vision Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Lifespan Vision Ventures?

Public channels for Lifespan Vision Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Lifespan Vision Ventures?

The team at Lifespan Vision Ventures includes Altar Munis (Associate). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co